KR20020067566A - 도파민 신경전달 조절제 - Google Patents
도파민 신경전달 조절제 Download PDFInfo
- Publication number
- KR20020067566A KR20020067566A KR1020027008067A KR20027008067A KR20020067566A KR 20020067566 A KR20020067566 A KR 20020067566A KR 1020027008067 A KR1020027008067 A KR 1020027008067A KR 20027008067 A KR20027008067 A KR 20027008067A KR 20020067566 A KR20020067566 A KR 20020067566A
- Authority
- KR
- South Korea
- Prior art keywords
- disorders
- group
- pharmaceutical composition
- disease
- disorder
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims description 48
- 229960003638 dopamine Drugs 0.000 title claims description 23
- 230000005062 synaptic transmission Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 130
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 42
- -1 3,3,3-trifluoropropyl Chemical group 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 6
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 5
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 3
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 33
- 208000035475 disorder Diseases 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 26
- 208000028017 Psychotic disease Diseases 0.000 claims description 21
- 208000024891 symptom Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 201000000980 schizophrenia Diseases 0.000 claims description 13
- 208000019022 Mood disease Diseases 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 208000012661 Dyskinesia Diseases 0.000 claims description 7
- 208000015114 central nervous system disease Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 208000019116 sleep disease Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 6
- 231100000869 headache Toxicity 0.000 claims description 6
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 208000003028 Stuttering Diseases 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000007659 motor function Effects 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 208000027765 speech disease Diseases 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000012239 Developmental disease Diseases 0.000 claims description 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 230000003920 cognitive function Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 208000027534 Emotional disease Diseases 0.000 claims description 3
- 208000004547 Hallucinations Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000036626 Mental retardation Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 3
- 239000002574 poison Substances 0.000 claims 3
- 231100000614 poison Toxicity 0.000 claims 3
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 208000037821 progressive disease Diseases 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 230000004970 emotional disturbance Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 101100203601 Caenorhabditis elegans sor-3 gene Proteins 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 230000003542 behavioural effect Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 102000015554 Dopamine receptor Human genes 0.000 description 11
- 108050004812 Dopamine receptor Proteins 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 210000001577 neostriatum Anatomy 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 9
- 230000003291 dopaminomimetic effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 229940076279 serotonin Drugs 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- BFFDEVPWGSZYSN-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)piperidine Chemical compound CS(=O)(=O)C1=CC=CC(C2CCNCC2)=C1 BFFDEVPWGSZYSN-UHFFFAOYSA-N 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 229960000632 dexamfetamine Drugs 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 6
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940052760 dopamine agonists Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 150000004885 piperazines Chemical class 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229910052723 transition metal Inorganic materials 0.000 description 5
- 150000003624 transition metals Chemical class 0.000 description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 5
- HPUYFCNUROWQBG-UHFFFAOYSA-N 3-(1-propylpiperidin-4-yl)phenol Chemical compound C1CN(CCC)CCC1C1=CC=CC(O)=C1 HPUYFCNUROWQBG-UHFFFAOYSA-N 0.000 description 4
- FINLIMGQGJZNRN-UHFFFAOYSA-N 3-piperidin-4-ylphenol Chemical compound OC1=CC=CC(C2CCNCC2)=C1 FINLIMGQGJZNRN-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- URTZYOXTRYKMOC-UHFFFAOYSA-N 3-(1-ethylpiperidin-4-yl)phenol Chemical compound C1CN(CC)CCC1C1=CC=CC(O)=C1 URTZYOXTRYKMOC-UHFFFAOYSA-N 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- NONQCMNVMIGQEE-UHFFFAOYSA-N 4-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CCNCC2)=C1 NONQCMNVMIGQEE-UHFFFAOYSA-N 0.000 description 3
- XPQIKGMGTVAKLA-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1-propylpiperidine Chemical compound C1CN(CCC)CCC1C1=CC=C(S(C)(=O)=O)C=C1 XPQIKGMGTVAKLA-UHFFFAOYSA-N 0.000 description 3
- IPKSNWXGEIHOMR-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]piperidine Chemical compound FC(F)(F)C1=CC=CC(C2CCNCC2)=C1 IPKSNWXGEIHOMR-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000009985 drug-induced dyskinesia Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- QTXMJVVQULMGMP-UHFFFAOYSA-N methyl 4-(3-methylsulfanylphenyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC)CCC(C=2C=C(SC)C=CC=2)=C1 QTXMJVVQULMGMP-UHFFFAOYSA-N 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000003982 sigma receptor ligand Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 125000005270 trialkylamine group Chemical group 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- IIFAQXPNYXJBMU-UHFFFAOYSA-N 1-(3-methylsulfonylphenyl)-4-propylpiperazine Chemical compound C1CN(CCC)CCN1C1=CC=CC(S(C)(=O)=O)=C1 IIFAQXPNYXJBMU-UHFFFAOYSA-N 0.000 description 2
- PVXHTUGKUYQLCU-UHFFFAOYSA-N 1-(3-methylsulfonylphenyl)piperazine Chemical compound CS(=O)(=O)C1=CC=CC(N2CCNCC2)=C1 PVXHTUGKUYQLCU-UHFFFAOYSA-N 0.000 description 2
- IHQGFLMQQFOKNI-UHFFFAOYSA-N 1-benzyl-4-(3-methoxyphenyl)-3,6-dihydro-2h-pyridine Chemical compound COC1=CC=CC(C=2CCN(CC=3C=CC=CC=3)CC=2)=C1 IHQGFLMQQFOKNI-UHFFFAOYSA-N 0.000 description 2
- KOPPWFMKOOMORI-UHFFFAOYSA-N 1-benzyl-4-(3-methylsulfonylphenyl)piperidine Chemical compound CS(=O)(=O)C1=CC=CC(C2CCN(CC=3C=CC=CC=3)CC2)=C1 KOPPWFMKOOMORI-UHFFFAOYSA-N 0.000 description 2
- VHAFOFLCIMSUTR-UHFFFAOYSA-N 1-bromo-3-(trifluoromethylsulfonyl)benzene Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(Br)=C1 VHAFOFLCIMSUTR-UHFFFAOYSA-N 0.000 description 2
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
- CJECWLYDUGXHQJ-UHFFFAOYSA-N 3-(1-butylpiperidin-4-yl)phenol Chemical compound C1CN(CCCC)CCC1C1=CC=CC(O)=C1 CJECWLYDUGXHQJ-UHFFFAOYSA-N 0.000 description 2
- OGAPNZQIKTVCGR-UHFFFAOYSA-N 3-(1-propylpiperidin-4-yl)benzamide Chemical compound C1CN(CCC)CCC1C1=CC=CC(C(N)=O)=C1 OGAPNZQIKTVCGR-UHFFFAOYSA-N 0.000 description 2
- JEBBVQHLUNJCDO-UHFFFAOYSA-N 3-(1-propylpiperidin-4-yl)benzonitrile Chemical compound C1CN(CCC)CCC1C1=CC=CC(C#N)=C1 JEBBVQHLUNJCDO-UHFFFAOYSA-N 0.000 description 2
- PZPVLBXASPDCHR-UHFFFAOYSA-N 3-(4-propylpiperazin-1-yl)benzonitrile Chemical compound C1CN(CCC)CCN1C1=CC=CC(C#N)=C1 PZPVLBXASPDCHR-UHFFFAOYSA-N 0.000 description 2
- SNWOGYXQQFQOME-UHFFFAOYSA-N 4-(3-methylsulfanylphenyl)-1,2,3,6-tetrahydropyridine Chemical compound CSC1=CC=CC(C=2CCNCC=2)=C1 SNWOGYXQQFQOME-UHFFFAOYSA-N 0.000 description 2
- YASJRXKKKXFQGV-UHFFFAOYSA-N 4-[3-(trifluoromethylsulfonyl)phenyl]pyridine Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(C=2C=CN=CC=2)=C1 YASJRXKKKXFQGV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020852 Hypertonia Diseases 0.000 description 2
- 208000030990 Impulse-control disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- IYCTUYDLAODTNH-UHFFFAOYSA-N [3-(1-propylpiperidin-4-yl)phenyl] methanesulfonate Chemical compound C1CN(CCC)CCC1C1=CC=CC(OS(C)(=O)=O)=C1 IYCTUYDLAODTNH-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000010249 dopaminergic function Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 208000022821 personality disease Diseases 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 108010085082 sigma receptors Proteins 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical group C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CXGGCNYHKKNQGW-UHFFFAOYSA-N 1-(2-methoxyphenyl)-4-propylpiperazine Chemical compound C1CN(CCC)CCN1C1=CC=CC=C1OC CXGGCNYHKKNQGW-UHFFFAOYSA-N 0.000 description 1
- SWUAJBUQZVCJIA-UHFFFAOYSA-N 1-(2-methylpropyl)-4-(3-methylsulfonylphenyl)piperidine Chemical compound C1CN(CC(C)C)CCC1C1=CC=CC(S(C)(=O)=O)=C1 SWUAJBUQZVCJIA-UHFFFAOYSA-N 0.000 description 1
- SQJJIPWVYJPFNA-UHFFFAOYSA-N 1-(2-phenylethyl)-4-[3-(trifluoromethyl)phenyl]piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC=3C=CC=CC=3)CC2)=C1 SQJJIPWVYJPFNA-UHFFFAOYSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- OZUAYVYYMFVLEW-UHFFFAOYSA-N 1-(3-piperazin-1-ylphenyl)ethanone Chemical compound CC(=O)C1=CC=CC(N2CCNCC2)=C1 OZUAYVYYMFVLEW-UHFFFAOYSA-N 0.000 description 1
- ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-butanol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCN1C1=NC=C(F)C=N1 ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 0.000 description 1
- TWTHRLPOEZZQDP-UHFFFAOYSA-N 1-[3-(1-propylpiperidin-4-yl)phenyl]ethanone Chemical compound C1CN(CCC)CCC1C1=CC=CC(C(C)=O)=C1 TWTHRLPOEZZQDP-UHFFFAOYSA-N 0.000 description 1
- IGUBHMOKZQPRGE-UHFFFAOYSA-N 1-[3-(4-propylpiperazin-1-yl)phenyl]ethanone Chemical compound C1CN(CCC)CCN1C1=CC=CC(C(C)=O)=C1 IGUBHMOKZQPRGE-UHFFFAOYSA-N 0.000 description 1
- NZTYVGVVZBNRIG-UHFFFAOYSA-N 1-[3-(trifluoromethylsulfonyl)phenyl]piperazine Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(N2CCNCC2)=C1 NZTYVGVVZBNRIG-UHFFFAOYSA-N 0.000 description 1
- UYMKVWIIAQEYEC-UHFFFAOYSA-N 1-benzyl-4-(3-methoxyphenyl)piperidin-4-ol Chemical compound COC1=CC=CC(C2(O)CCN(CC=3C=CC=CC=3)CC2)=C1 UYMKVWIIAQEYEC-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- NKYFJZAKUPSUSH-UHFFFAOYSA-N 1-bromo-3-methylsulfanylbenzene Chemical compound CSC1=CC=CC(Br)=C1 NKYFJZAKUPSUSH-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- HLHHKXAMCGCSLT-UHFFFAOYSA-N 1-butyl-4-(3-methylsulfonylphenyl)piperidine Chemical compound C1CN(CCCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 HLHHKXAMCGCSLT-UHFFFAOYSA-N 0.000 description 1
- QLGKBJUAKLXOAT-UHFFFAOYSA-N 1-butyl-4-[3-(trifluoromethyl)phenyl]piperidine Chemical compound C1CN(CCCC)CCC1C1=CC=CC(C(F)(F)F)=C1 QLGKBJUAKLXOAT-UHFFFAOYSA-N 0.000 description 1
- BUKAYQGWHYPNKN-UHFFFAOYSA-N 1-ethyl-4-(3-methylsulfonylphenyl)piperidine Chemical compound C1CN(CC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 BUKAYQGWHYPNKN-UHFFFAOYSA-N 0.000 description 1
- IGISPMBUGPHLBY-UHFFFAOYSA-N 1-iodo-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(I)=C1 IGISPMBUGPHLBY-UHFFFAOYSA-N 0.000 description 1
- SLEQRFMTAWGXRG-UHFFFAOYSA-N 1-phenyl-4-propylpiperazine Chemical compound C1CN(CCC)CCN1C1=CC=CC=C1 SLEQRFMTAWGXRG-UHFFFAOYSA-N 0.000 description 1
- FUQLXDOPKSKERF-UHFFFAOYSA-N 1-propyl-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1N(CCC)CCC(C=2C=C(C=CC=2)C(F)(F)F)=C1 FUQLXDOPKSKERF-UHFFFAOYSA-N 0.000 description 1
- WTJJXQCQGLLXNZ-UHFFFAOYSA-N 1-propyl-4-[3-(trifluoromethyl)phenyl]piperidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(C(F)(F)F)=C1 WTJJXQCQGLLXNZ-UHFFFAOYSA-N 0.000 description 1
- INAIFFKBSXBWGO-UHFFFAOYSA-N 1-propyl-4-[3-(trifluoromethylsulfonyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1N(CCC)CCC(C=2C=C(C=CC=2)S(=O)(=O)C(F)(F)F)=C1 INAIFFKBSXBWGO-UHFFFAOYSA-N 0.000 description 1
- VBKQDBLQDXWTRJ-UHFFFAOYSA-N 1-propyl-4-[3-(trifluoromethylsulfonyl)phenyl]piperazine Chemical compound C1CN(CCC)CCN1C1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 VBKQDBLQDXWTRJ-UHFFFAOYSA-N 0.000 description 1
- WRHIHRXLCMBVOL-UHFFFAOYSA-N 1-propyl-4-[3-(trifluoromethylsulfonyl)phenyl]piperidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 WRHIHRXLCMBVOL-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- IVJLGIMHHWKRAN-UHFFFAOYSA-N 2-(chloromethyl)oxolane Chemical compound ClCC1CCCO1 IVJLGIMHHWKRAN-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- BPNZNQGAIFMNES-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)phenol Chemical compound OC1=CC=CC(C2CCN(CC=3C=CC=CC=3)CC2)=C1 BPNZNQGAIFMNES-UHFFFAOYSA-N 0.000 description 1
- AWROKCIGUWAVRF-UHFFFAOYSA-N 3-(4-propylpiperazin-1-yl)phenol Chemical compound C1CN(CCC)CCN1C1=CC=CC(O)=C1 AWROKCIGUWAVRF-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- JTQJRJLDKOSNJF-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1,2,3,6-tetrahydropyridine Chemical compound CS(=O)(=O)C1=CC=CC(C=2CCNCC=2)=C1 JTQJRJLDKOSNJF-UHFFFAOYSA-N 0.000 description 1
- FKTBSZQOHQBTBG-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-(oxolan-2-ylmethyl)piperidine Chemical compound CS(=O)(=O)C1=CC=CC(C2CCN(CC3OCCC3)CC2)=C1 FKTBSZQOHQBTBG-UHFFFAOYSA-N 0.000 description 1
- REHNKEZREAXORH-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propan-2-ylpiperidine Chemical compound C1CN(C(C)C)CCC1C1=CC=CC(S(C)(=O)=O)=C1 REHNKEZREAXORH-UHFFFAOYSA-N 0.000 description 1
- DIXPHRIXQYGPLM-UHFFFAOYSA-N 4-phenyl-1-propylpiperidine Chemical compound C1CN(CCC)CCC1C1=CC=CC=C1 DIXPHRIXQYGPLM-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical class C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- UBVQZPMYJSYIHI-UHFFFAOYSA-N CCC(C)OC(=O)N1CCC(=O)CC1 Chemical compound CCC(C)OC(=O)N1CCC(=O)CC1 UBVQZPMYJSYIHI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- SBUKLPSBNFWJCU-UHFFFAOYSA-N ClIBr Chemical compound ClIBr SBUKLPSBNFWJCU-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000000860 Compassion Fatigue Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000021584 Expressive language disease Diseases 0.000 description 1
- UGFLAEXXUBMGME-UHFFFAOYSA-N FC(F)(F)C1=CC=CC(C2CCN(CC=3C=CC=CC=3)CC2)=C1 Chemical compound FC(F)(F)C1=CC=CC(C2CCN(CC=3C=CC=CC=3)CC2)=C1 UGFLAEXXUBMGME-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000019896 Motor Skills disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- BBVXCTMITMQVAX-UHFFFAOYSA-N N1CCNCC1.ClC1=C(C=CC=C1)O Chemical compound N1CCNCC1.ClC1=C(C=CC=C1)O BBVXCTMITMQVAX-UHFFFAOYSA-N 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000036353 Rett disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229940122490 Sigma receptor antagonist Drugs 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000028790 Speech Sound disease Diseases 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 208000011962 Substance-induced mood disease Diseases 0.000 description 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- JMLIJLNEJPQGDV-UHFFFAOYSA-N [3-(1-butylpiperidin-4-yl)phenyl] methanesulfonate Chemical compound C1CN(CCCC)CCC1C1=CC=CC(OS(C)(=O)=O)=C1 JMLIJLNEJPQGDV-UHFFFAOYSA-N 0.000 description 1
- BYVJNZIXZDUHST-UHFFFAOYSA-N [3-(1-ethylpiperidin-4-yl)phenyl] methanesulfonate Chemical compound C1CN(CC)CCC1C1=CC=CC(OS(C)(=O)=O)=C1 BYVJNZIXZDUHST-UHFFFAOYSA-N 0.000 description 1
- SCANEWNZJMVALU-UHFFFAOYSA-N [3-(1-ethylpiperidin-4-yl)phenyl] trifluoromethanesulfonate Chemical compound C1CN(CC)CCC1C1=CC=CC(OS(=O)(=O)C(F)(F)F)=C1 SCANEWNZJMVALU-UHFFFAOYSA-N 0.000 description 1
- MGMFHKURJDAQBG-UHFFFAOYSA-N [3-(1-propylpiperidin-4-yl)phenyl] trifluoromethanesulfonate Chemical compound C1CN(CCC)CCC1C1=CC=CC(OS(=O)(=O)C(F)(F)F)=C1 MGMFHKURJDAQBG-UHFFFAOYSA-N 0.000 description 1
- OWLZUFIBDOBKER-UHFFFAOYSA-N [3-(4-propylpiperazin-1-yl)phenyl] methanesulfonate Chemical compound C1CN(CCC)CCN1C1=CC=CC(OS(C)(=O)=O)=C1 OWLZUFIBDOBKER-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- DMBGJKAHPVZTEB-UHFFFAOYSA-N methyl 3-(1-propylpiperidin-4-yl)benzoate Chemical compound C1CN(CCC)CCC1C1=CC=CC(C(=O)OC)=C1 DMBGJKAHPVZTEB-UHFFFAOYSA-N 0.000 description 1
- GAOMYCJWQJHIBY-UHFFFAOYSA-N methyl 4-(3-methylsulfonylphenyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 GAOMYCJWQJHIBY-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006464 oxidative addition reaction Methods 0.000 description 1
- OTYPIDNRISCWQY-UHFFFAOYSA-L palladium(2+);tris(2-methylphenyl)phosphane;dichloride Chemical compound Cl[Pd]Cl.CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C.CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C OTYPIDNRISCWQY-UHFFFAOYSA-L 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229950004933 rimcazole Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
- MPCBFZJWRUFXRZ-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(3-methylsulfanylphenyl)piperidine-1-carboxylate Chemical compound CSC1=CC=CC(C2(O)CCN(CC2)C(=O)OC(C)(C)C)=C1 MPCBFZJWRUFXRZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Description
Claims (36)
- 하기 화학식(I)의 3-치환된 4-(페닐-N-알킬)-피페라진 또는 4-(페닐-N-알킬)-피페리딘 또는 이것의 약제학적으로 허용가능한 염:상기 식에서,X는 N, CH 및 C로 이루어지는 군으로부터 선택되나, 화합물이 점선에서 이중결합을 포함하는 경우에 X는 C만일 수 있으며,R1은 OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2및 CONHR3로 이루어진 군으로부터 선택되며, R3는 하기에 정의되는 바와 같고, X가 CH 또는 C인 경우에 R1은 또한 CF3, CN, F, Cl, Br 및 I로 이루어진 군으로부터 선택될 수 있으며;R2는 C1-C4알킬, 알릴, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-트리플루오로프로필, 4,4,4-트리플루오로부틸 및 -(CH2)-R4으로 이루어지는 군으로부터 선택되며, R4는 하기에 정의되는 바와 같으며;R3는 C1-C3알킬, CF3및 N(R2)2로 이루어지는 군으로부터 선택되며, R2는 상기에 정의된 바와 같으며;R4는 C3-C6시클로알킬, 2-테트라히드로푸란 및 3-테트라-히드로푸란으로 이루어진 군으로부터 선택된다.
- 제 1항에 있어서, X가 CH 또는 C임을 특징으로 하는 화합물.
- 제 1항 또는 제 2항에 있어서, R1이 OSO2CF3, OSO2CH3, SO2CH3, SO2CF3, COCH3, CF3, CN, CON(CH3)2및 SO2N(CH3)2으로 이루어진 군으로부터 선택됨을 특징으로 하는 화합물.
- 제 1항 내지 제 3항 중 어느 한 항에 있어서, X이 CH임을 특징으로 하는 화합물.
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, R1이 SO2CF3, SO2CH3, COCH3, CF3및 CN으로 이루어진 군으로부터 선택되고, X가 CH임을 특징으로 하는 화합물.
- 제 1항 내지 제 5항 중 어느 한 항에 있어서, R2가 n-프로필 및 에틸로 이루어지는 군으로부터 선택됨을 특징으로 하는 화합물.
- 제 1항 내지 제 6항 중 어느 한 항에 있어서, X가 CH이고, R1이 SO2CH3이고, R2가 n-프로필임을 특징으로 하는 화합물.
- 제 1항 내지 제 7항 중 어느 한 항에 있어서, 화합물이 4-(3-메탄술포닐-페닐)-1-프로필-피페리딘임을 특징으로 하는 화합물.
- 제 1항 내지 제 8항 중 어느 한 항에 따른 화합물을 포함하는 약제 조성물.
- 제 9항에 있어서, 중추 신경계 장애를 치료하기 위한 약제 조성물.
- 제 10항에 있어서, 도파민 매개된 장애를 치료하기 위한 약제 조성물.
- 제 9항 내지 제 11항 중 어느 한 항에 있어서, 의인성 파킨슨씨병과 비의인성 파킨슨씨병, 이상 운동증 및 긴장증과 같은 운동 장애; 틱병(tics); 진전병(tremor); 뚜렛병(Tourette's disease); 말더듬 및 기타 언어 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 약제 조성물.
- 제 9항 내지 제 11항 중 어느 한 항에 있어서, 정신분열증 및 정신분열형 장애를 포함하는 의인성 및 비의인성 정신병 및 환각증으로 이루어지는 군으로부터선택된 증상을 치료하기 위한 약제 조성물.
- 제 9항 내지 제 11항 중 어느 한 항에 있어서, 매노디프레시브 질환(manodepressive illness), 우울증 및 강박증을 포함하는 기분 및 불안 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 약제 조성물..
- 제 9항 내지 제 11항 중 어느 한 항에 있어서, 주의력 결핍 장애, 자폐증, 운동 완만증, 정신 완서증 및 인지 기능 장애를 포함하는 신경발달 장애 및 연령 관련 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 약제 조성물.
- 제 9항 내지 제 11항 중 어느 한 항에 있어서, 수면 장애, 성기능 장애, 식이 장애, 비만 및 두통과 기타 동통으로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 약제 조성물.
- 제 9항 내지 제 11항 중 어느 한 항에 있어서, 운동 기능, 인지 기능 및 신경퇴행성 장애와 발달 장애와 관련된 감정 장애를 개선시키기 위한, 그리고 외상, 독, 염증, 감염, 종양, 혈관, 저산소 또는 대사 작용에 의해서 유발된 뇌 손상 후에 발병되는 정신분열증 및 정신분열형 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 약제 조성물.
- 제 9항 내지 제 11항 중 어느 한 항에 있어서, 물질 관련 장애를 치료하기 위한 약제 조성물.
- 중추 신경계 장애 치료용 약제 조성물을 제조하기 위한 제 1항 내지 제 8항 중 어느 한 항에 따른 화합물의 용도.
- 제 19항에 있어서, 약제 조성물이 도파민 매개된 장애를 치료하기 위한 것임을 특징으로 하는 용도.
- 제 19항 또는 제 20항에 있어서, 약제 조성물이 의인성 파킨슨씨병과 비의인성 파킨슨씨병, 이상 운동증 및 긴장증과 같은 운동 장애; 틱병; 진전병; 뚜렛병; 말더듬 및 기타 언어 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 것임을 특징으로 하는 용도.
- 제 19항 또는 제 20항에 있어서, 약제 조성물이 정신분열증 및 정신분열형 장애를 포함하는 의인성 및 비의인성 정신병, 및 환각증으로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 것임을 특징으로 하는 용도.
- 제 19항 또는 제 20항에 있어서, 약제 조성물이 매노디프레시브 질환, 우울증 및 강박증을 포함하는 기분 및 불안 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 것임을 특징으로 하는 용도.
- 제 19항 또는 제 20항에 있어서, 약제 조성물이 주의력 결핍 장애, 자폐증, 운동 완만증, 정신 완서증 및 인지 기능 장애를 포함하는 신경발달 장애 및 연령 관련 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 것임을 특징으로 하는 용도.
- 제 19항 또는 제 20항에 있어서, 약제 조성물이 수면 장애, 성기능 장애, 식이 장애, 비만 및 두통과 기타 동통으로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 것임을 특징으로 하는 용도.
- 제 19항 또는 제 20항에 있어서, 약제 조성물이 운동 기능, 인지 기능 및 신경퇴행성 장애와 발달 장애와 관련된 감정 장애를 개선시키기 위한, 그리고 외상, 독, 염증, 감염, 종양, 혈관, 저산소 또는 대사 작용에 의해서 유발된 뇌 손상 후에 발병되는 정신분열증 및 정신분열형 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 것임을 특징으로 하는 용도.
- 제 19항 또는 제 20항에 있어서, 약제 조성물이 물질 관련 장애를 치료하기 위한 것임을 특징으로 하는 약제 조성물.
- 약제학적 활성량의 제 1항 내지 제 8중 어느 한 항에 따른 화합물을 환자에게 투여하여 환자의 중추 신경계의 장애를 치료하는 방법.
- 제 28에 있어서, 도파민 매개된 장애를 치료하기 위한 방법.
- 제 28항 또는 제 29항에 있어서, 의인성 파킨슨씨병과 비의인성 파킨슨씨병, 이상 운동증 및 긴장증과 같은 운동 장애; 틱병; 진전병; 뚜렛병; 말더듬 및 기타 언어 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 방법.
- 제 28항 또는 제 29항에 있어서, 정신분열증 및 정신분열형 장애를 포함하는 의인성 및 비의인성 정신병, 및 환각증으로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 방법.
- 제 28항 또는 제 29항에 있어서, 매노디프레시브 질환, 우울증 및 강박증을 포함하는 기분 및 불안 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 방법.
- 제 28항 또는 제 29항에 있어서, 주의력 결핍 장애, 자폐증, 운동 완만증, 정신 완서증 및 인지 기능 장애를 포함하는 신경발달 장애 및 연령 관련 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 방법.
- 제 28항 또는 제 29항에 있어서, 수면 장애, 성기능 장애, 식이 장애, 비만 및 두통과 기타 동통으로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 방법.
- 제 28항 또는 제 29항에 있어서, 운동 기능, 인지 기능 및 신경퇴행성 장애와 발달 장애와 관련된 감정 장애를 개선시키기 위한, 그리고 외상, 독, 염증, 감염, 종양, 혈관, 저산소 또는 대사 작용에 의해서 유발된 뇌 손상 후에 발병되는 정신 분열증 및 정신분열형 장애로 이루어지는 군으로부터 선택된 증상을 치료하기 위한 방법.
- 제 28항 또는 제 29항에 있어서, 물질 관련 장애를 치료하기 위한 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904724-3 | 1999-12-22 | ||
SE9904724A SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | New modulators of dopamine neurotransmission I |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057024520A Division KR100690133B1 (ko) | 1999-12-22 | 2000-12-22 | 도파민 신경전달 조절제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020067566A true KR20020067566A (ko) | 2002-08-22 |
KR100779288B1 KR100779288B1 (ko) | 2007-11-27 |
Family
ID=20418253
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027008067A KR100779288B1 (ko) | 1999-12-22 | 2000-12-22 | 도파민 신경전달 조절제 |
KR1020057024520A KR100690133B1 (ko) | 1999-12-22 | 2000-12-22 | 도파민 신경전달 조절제 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057024520A KR100690133B1 (ko) | 1999-12-22 | 2000-12-22 | 도파민 신경전달 조절제 |
Country Status (30)
Country | Link |
---|---|
US (3) | US6903120B2 (ko) |
EP (3) | EP1240142B1 (ko) |
JP (3) | JP4975928B2 (ko) |
KR (2) | KR100779288B1 (ko) |
CN (2) | CN1255382C (ko) |
AT (3) | ATE254601T1 (ko) |
AU (2) | AU778422B2 (ko) |
BG (2) | BG110211A (ko) |
BR (1) | BR0016611B1 (ko) |
CA (1) | CA2394602C (ko) |
CZ (1) | CZ303302B6 (ko) |
DE (3) | DE60006717T2 (ko) |
DK (1) | DK1240142T3 (ko) |
EE (2) | EE200900004A (ko) |
ES (2) | ES2246926T3 (ko) |
HK (2) | HK1054229B (ko) |
HR (2) | HRP20020540B1 (ko) |
HU (1) | HU229605B1 (ko) |
IL (3) | IL150351A0 (ko) |
MX (1) | MXPA02006320A (ko) |
NO (2) | NO323436B1 (ko) |
NZ (2) | NZ519595A (ko) |
PL (1) | PL205093B1 (ko) |
RU (2) | RU2386623C2 (ko) |
SE (1) | SE9904724D0 (ko) |
SI (1) | SI1240142T1 (ko) |
SK (1) | SK287367B6 (ko) |
UA (1) | UA73338C2 (ko) |
WO (2) | WO2001046144A1 (ko) |
ZA (1) | ZA200204812B (ko) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
PE20020690A1 (es) * | 2000-11-03 | 2002-08-23 | Upjohn Co | Metodo y tratamiento y prevencion de los dolores de cabeza de migranas |
AU2002324846B2 (en) * | 2001-08-31 | 2007-05-10 | Childrens Hospital Medical Center | Phosphodiesterase activity and regulation of phosphodiesterase 1-B-mediated signaling in brain |
US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
DE602005017784D1 (de) * | 2004-06-08 | 2009-12-31 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission |
DK1773772T3 (da) | 2004-06-08 | 2010-09-13 | Nsab Af Neurosearch Sweden Ab | Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission |
AU2005254726A1 (en) * | 2004-06-18 | 2005-12-29 | Neurosearch A/S | Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
NZ555095A (en) * | 2004-10-13 | 2010-07-30 | Nsab Af Neurosearch Sweden Ab | Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines |
EP1802573B1 (en) * | 2004-10-13 | 2016-09-28 | Teva Pharmaceuticals International GmbH | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
DE602006007550D1 (de) * | 2005-02-10 | 2009-08-13 | Neurosearch As | Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren |
SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
WO2007065655A1 (en) | 2005-12-07 | 2007-06-14 | Neurosearch Sweden Ab | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
CN101400676A (zh) * | 2006-03-10 | 2009-04-01 | 纽约州州立大学研究基金会 | 具有中枢神经系统活性的托烷类前药 |
CA2667510A1 (en) * | 2006-10-27 | 2008-06-12 | Janssen Pharmaceutica N.V. | Methods for treating disruptive behavior disorders |
AU2007346591A1 (en) * | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
EP2146961B1 (en) * | 2007-04-12 | 2014-01-29 | IVAX International GmbH | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
CA2689692A1 (en) | 2007-06-05 | 2008-12-11 | Clas Sonesson | New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
EP2170327B1 (en) * | 2007-06-18 | 2014-10-22 | A.Carlsson Research AB | Use of dopamine stabilizers |
KR20100135325A (ko) * | 2008-04-29 | 2010-12-24 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 도파민 신경전달의 조절제 |
US20110105462A1 (en) * | 2008-04-29 | 2011-05-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
AU2009242095A1 (en) * | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
SG10201507362TA (en) | 2009-08-05 | 2015-10-29 | Intra Cellular Therapies Inc | Novel Regulatory Proteins And Inhibitors |
JP6173693B2 (ja) * | 2010-02-24 | 2017-08-02 | リサーチ・トライアングル・インスティチュート | アリールピペラジンオピオイド受容体アンタゴニスト |
WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
EP2611759A1 (en) * | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
EP2618826B1 (en) * | 2010-09-20 | 2016-04-13 | A.Carlsson Research AB | Phenylpiperidine compounds for the treatment of dementia |
EA023462B1 (ru) | 2011-09-07 | 2016-06-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Полиморфная форма гидрохлорида придопидина |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
EA027748B1 (ru) | 2012-04-04 | 2017-08-31 | Тева Фармасьютикалз Интернэшнл Гмбх | Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения |
CA2879020C (en) | 2012-07-12 | 2021-02-09 | Psyadon Pharmaceuticals, Inc. | Fused benzazepines for treatment of tourette's syndrome |
US20150216850A1 (en) * | 2012-09-27 | 2015-08-06 | Michael Hayden | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
AU2014281414A1 (en) | 2013-06-21 | 2016-01-21 | Teva Pharmaceuticals International Gmbh | Use of high dose pridopidine for treating Huntington's disease |
DK3057595T3 (da) * | 2013-10-18 | 2020-08-10 | Emalex Biosciences Inc | Smeltebenzazepiner til behandling af stammen |
ES2911800T3 (es) | 2014-01-22 | 2022-05-20 | Prilenia Neurotherapeutics Ltd | Formulaciones de liberación modificada de pridopidina |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
JP2018505147A (ja) | 2014-12-22 | 2018-02-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジンのl−酒石酸塩 |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
US10603311B2 (en) | 2015-02-25 | 2020-03-31 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
EP3294337A1 (en) | 2015-05-13 | 2018-03-21 | A.Carlsson Research AB | Treatment of debilitating fatigue |
AR105434A1 (es) * | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
CA3035099C (en) * | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
CN110505902B (zh) | 2017-01-20 | 2022-11-11 | 普瑞尼亚神经治疗有限公司 | 普利多匹定用于治疗脆性x综合征的应用 |
EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
MX2020001836A (es) | 2017-08-14 | 2020-08-10 | Prilenia Neurotherapeutics Ltd | Metodo para tratar esclerosis lateral amiotrofica con pridopidina. |
EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
MX2020002645A (es) | 2017-09-08 | 2021-06-10 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
WO2023049480A1 (en) * | 2021-09-25 | 2023-03-30 | Alexander Shulgin Research Institute | Substituted phenylalkylamines |
WO2023214412A1 (en) * | 2022-05-03 | 2023-11-09 | Prilenia Neurotherapeutics Ltd. | Processes and intermediates for the preparation of pridopidine |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB850662A (en) | 1956-10-22 | 1960-10-05 | Parke Davis & Co | Substituted piperazines and processes for their production |
BE662455A (ko) * | 1964-04-14 | |||
FR1459013A (fr) | 1964-08-05 | 1966-04-29 | Allen & Hanburys Ltd | Procédé de préparation de dérivés de la 4-phényl-pipéridine |
GB1060160A (en) * | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
ZA7546B (en) * | 1974-01-21 | 1976-08-25 | Parke Davis & Co | New antibacterial amide compounds and methods for their production |
GB1560271A (en) * | 1977-01-14 | 1980-02-06 | Joullie International Sa | Therapeutically useful m-trifluoromethylphenylpiperazine derivatives |
US4202898A (en) * | 1978-06-05 | 1980-05-13 | Synthelabo | Method of treating anxiety and depression |
FR2429212A1 (fr) * | 1978-06-20 | 1980-01-18 | Synthelabo | Derives de phenylpiperazine et leur application en therapeutique |
FR2459797A2 (fr) * | 1978-08-01 | 1981-01-16 | Synthelabo | Derives de phenyl-1 piperazine et leur application en therapeutique |
US4267328A (en) * | 1978-08-01 | 1981-05-12 | Synthelabo | 1-Phenylpiperazines |
US4333942A (en) | 1979-08-03 | 1982-06-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Anti-depressant and analgesic 4-phenoxypiperidines |
SE446335B (sv) * | 1982-03-30 | 1986-09-01 | Astra Laekemedel Ab | Ren enantiomer av en metasubstituerad 3-fenyl-1-propylpiperidin |
US4518712A (en) | 1980-06-30 | 1985-05-21 | Taiho Pharmaceutical Company Limited | Piperazine derivative and analgesic composition containing the same |
GB2083476B (en) | 1980-09-12 | 1984-02-08 | Wyeth John & Brother Ltd | Heterocyclic compounds |
FR2501506A1 (fr) * | 1981-03-11 | 1982-09-17 | Sanofi Sa | Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine |
US4415736A (en) | 1981-12-28 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Certain tetrahydropyridine intermediates |
EP0094159B1 (en) | 1982-05-10 | 1990-03-14 | Takeda Chemical Industries, Ltd. | Dihydropyridine derivatives, their production and use |
US4504660A (en) | 1982-07-06 | 1985-03-12 | American Home Products Corporation | Process for the production of 2,6-diaminobenzonitrile derivatives |
HU198454B (en) | 1987-12-14 | 1989-10-30 | Richter Gedeon Vegyeszet | Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds |
FR2639226B1 (fr) * | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
AU7162791A (en) * | 1989-12-27 | 1991-07-24 | Miroslav Radman | Novel system for isolating and producing new genes, gene products and dna sequences |
CA2071897A1 (en) * | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
ATE201669T1 (de) | 1991-04-17 | 2001-06-15 | Upjohn Co | Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten |
EP0591426A4 (en) * | 1991-06-27 | 1996-08-21 | Univ Virginia Commonwealth | Sigma receptor ligands and the use thereof |
IE914218A1 (en) | 1991-09-11 | 1993-03-24 | Mcneilab Inc | Novel 4-arylpiperazines and 4-arylpiperidines |
GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
ATE204262T1 (de) | 1991-09-18 | 2001-09-15 | Glaxo Group Ltd | Benzanilidderivate als 5-ht1d-antagonisten |
GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
CN1036395C (zh) * | 1992-03-19 | 1997-11-12 | 约翰韦恩兄弟有限公司 | 哌嗪衍生物的制备方法 |
US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
AU6470096A (en) | 1995-07-19 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused triazole compounds |
US5892041A (en) | 1996-08-12 | 1999-04-06 | Neurogen Corporation | Fused indolecarboxamides: dopamine receptor subtype specific ligands |
DE19637237A1 (de) * | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
CA2288172A1 (en) * | 1997-04-18 | 1998-10-29 | Smithkline Beecham P.L.C. | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
SE9702799D0 (sv) * | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
US6303627B1 (en) * | 1998-06-19 | 2001-10-16 | Eli Lilly And Company | Inhibitors of serotonin reuptake |
JP5035813B2 (ja) * | 1998-07-10 | 2012-09-26 | マサチューセッツ インスティテュート オブ テクノロジー | 金属用のリガンドおよびそれらに基づいて改善された金属触媒法 |
US6232326B1 (en) * | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
RU2243226C2 (ru) | 1999-06-22 | 2004-12-27 | НьюроСёрч А/С | Новые производные бензимидазола и содержащие эти соединения фармацевтические композиции |
SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
AU2001280599A1 (en) | 2000-07-15 | 2002-01-30 | Smith Kline Beecham Corporation | Compounds and methods |
ES2247298T3 (es) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
DK1773772T3 (da) * | 2004-06-08 | 2010-09-13 | Nsab Af Neurosearch Sweden Ab | Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission |
-
1999
- 1999-12-22 SE SE9904724A patent/SE9904724D0/xx unknown
-
2000
- 2000-12-22 CN CNB008182574A patent/CN1255382C/zh not_active Expired - Fee Related
- 2000-12-22 WO PCT/SE2000/002673 patent/WO2001046144A1/en active IP Right Grant
- 2000-12-22 EE EEP200900004A patent/EE200900004A/xx unknown
- 2000-12-22 BR BRPI0016611-1A patent/BR0016611B1/pt not_active IP Right Cessation
- 2000-12-22 KR KR1020027008067A patent/KR100779288B1/ko not_active IP Right Cessation
- 2000-12-22 AT AT00989161T patent/ATE254601T1/de not_active IP Right Cessation
- 2000-12-22 RU RU2005117612/04A patent/RU2386623C2/ru not_active IP Right Cessation
- 2000-12-22 AT AT03027033T patent/ATE491697T1/de not_active IP Right Cessation
- 2000-12-22 EP EP00989162A patent/EP1240142B1/en not_active Expired - Lifetime
- 2000-12-22 AU AU25705/01A patent/AU778422B2/en not_active Ceased
- 2000-12-22 US US10/168,173 patent/US6903120B2/en not_active Ceased
- 2000-12-22 PL PL362253A patent/PL205093B1/pl unknown
- 2000-12-22 NZ NZ519595A patent/NZ519595A/en not_active IP Right Cessation
- 2000-12-22 EP EP03027033A patent/EP1428822B1/en not_active Expired - Lifetime
- 2000-12-22 DE DE60006717T patent/DE60006717T2/de not_active Expired - Fee Related
- 2000-12-22 NZ NZ531680A patent/NZ531680A/en unknown
- 2000-12-22 CA CA002394602A patent/CA2394602C/en not_active Expired - Fee Related
- 2000-12-22 WO PCT/SE2000/002674 patent/WO2001046145A1/en active Application Filing
- 2000-12-22 MX MXPA02006320A patent/MXPA02006320A/es active IP Right Grant
- 2000-12-22 US US10/168,297 patent/US20030109532A1/en not_active Abandoned
- 2000-12-22 SK SK867-2002A patent/SK287367B6/sk not_active IP Right Cessation
- 2000-12-22 AU AU25704/01A patent/AU2570401A/en not_active Abandoned
- 2000-12-22 DE DE60045395T patent/DE60045395D1/de not_active Expired - Lifetime
- 2000-12-22 KR KR1020057024520A patent/KR100690133B1/ko not_active IP Right Cessation
- 2000-12-22 DK DK00989162T patent/DK1240142T3/da active
- 2000-12-22 DE DE60023345T patent/DE60023345T2/de not_active Expired - Lifetime
- 2000-12-22 SI SI200030761T patent/SI1240142T1/sl unknown
- 2000-12-22 CN CNB2005101194664A patent/CN100345833C/zh not_active Expired - Fee Related
- 2000-12-22 HU HU0203872A patent/HU229605B1/hu not_active IP Right Cessation
- 2000-12-22 RU RU2002119416/04A patent/RU2265013C2/ru not_active IP Right Cessation
- 2000-12-22 CZ CZ20022070A patent/CZ303302B6/cs not_active IP Right Cessation
- 2000-12-22 ES ES00989162T patent/ES2246926T3/es not_active Expired - Lifetime
- 2000-12-22 JP JP2001547056A patent/JP4975928B2/ja not_active Expired - Fee Related
- 2000-12-22 ES ES00989161T patent/ES2208461T3/es not_active Expired - Lifetime
- 2000-12-22 UA UA2002076055A patent/UA73338C2/uk unknown
- 2000-12-22 EE EEP200200344A patent/EE05135B1/xx not_active IP Right Cessation
- 2000-12-22 IL IL15035100A patent/IL150351A0/xx unknown
- 2000-12-22 AT AT00989162T patent/ATE307113T1/de active
- 2000-12-22 EP EP00989161A patent/EP1240141B1/en not_active Expired - Lifetime
-
2002
- 2002-06-14 ZA ZA200204812A patent/ZA200204812B/xx unknown
- 2002-06-17 NO NO20022878A patent/NO323436B1/no not_active IP Right Cessation
- 2002-06-19 BG BG110211A patent/BG110211A/en unknown
- 2002-06-19 BG BG106841A patent/BG65854B1/bg unknown
- 2002-06-20 IL IL150351A patent/IL150351A/en not_active IP Right Cessation
- 2002-06-20 HR HR20020540A patent/HRP20020540B1/xx not_active IP Right Cessation
-
2003
- 2003-09-09 HK HK03106411.5A patent/HK1054229B/zh not_active IP Right Cessation
-
2004
- 2004-12-21 US US11/016,967 patent/US7417043B2/en not_active Expired - Fee Related
-
2005
- 2005-09-07 HR HR20050784A patent/HRP20050784A2/hr not_active Application Discontinuation
-
2006
- 2006-11-01 HK HK06111978A patent/HK1091482A1/xx not_active IP Right Cessation
- 2006-12-15 NO NO20065825A patent/NO324874B1/no not_active IP Right Cessation
-
2007
- 2007-10-07 IL IL186448A patent/IL186448A0/en unknown
-
2008
- 2008-06-17 JP JP2008158572A patent/JP2009007358A/ja active Pending
-
2011
- 2011-05-24 JP JP2011116406A patent/JP5542740B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20020067566A (ko) | 도파민 신경전달 조절제 | |
KR100771287B1 (ko) | 도파민 신경전달 조절제 | |
USRE46117E1 (en) | Modulators of dopamine neurotransmission | |
AU2005200729B2 (en) | New modulators of dopamine neurotransmission |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121031 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131107 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151105 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161111 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171109 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |